POS0184 U-SHAPED ASSOCIATION OF SERUM URATE WITH ALL-CAUSE MORTALITY IN GOUT PATIENTS: NHANES 2007-2018

N. Chen,Q. H. LI,S. X. Hu,H. Lin,L. Dai

DOI: https://doi.org/10.1136/annrheumdis-2023-eular.3841

2023-01-01

Abstract:Background The EULAR guideline for the management of gout recommended a target serum urate (sUA) level of less than 6 mg/dl in gout patients and less than 5 mg/dl in tophaceous gout patients [1]. This recommendation is based on the evidence that achieving these targets will reduce gout attacks and tophi size. However, less is known about the impact of sUA on mortality in gout patients. Objectives To explore the relationship between sUA level and all-cause mortality in gout patients. Methods The present prospective cohort study included participants 20 years or older with gout enrolled from the 2007-2008 through 2017-2018 annual NHANES cycles. The data of mortality and its underlying causes to 31 December 2019 were obtained from the National Death Index records. The relationship of gout patients between sUA level and mortality were analyzed by Cox proportional hazards analysis, the restricted cubic spline regression analysis and two piece-wise regression model. Results A total of 1442 gout patients were included with median follow-up period 63 (interquartile range, 33-102) months. Compared with gout patients with sUA less than 6mg/dl, gout patients with sUA>6mg/dl were characterized by greater age, more often men, higher BMI and higher prevalence of hyperlipidemia (P <0.05). Cox proportional hazards analysis showed that sUA was a risk factor of mortality (HR 1.09, 95% CI 1.02 to 1.16) after adjusted by age, sex, race, education, BMI, smoking, cardiovascular disease, hyperlipidemia, hypertension and diabetes mellitus. However, restricted cubic spline regression analysis showed a U-shaped relationship between sUA and all-cause mortality (Pnon-linear <0.001, Figure 1). Two piece-wise regression model revealed sUA level of 6.2 mg/dl corresponded to the lowest mortality risk. For those patients with sUA less than 6mg/dl, the risk of all-cause death was borderline reduced 12% (HR 0.88, 95% CI 0.72 to 1.07) with each sUA unit increase. After 6 mg/dl, the risk of all-cause death increased 26% (HR 1.26, 95% CI 1.14 to 1.40) for each sUA unit increase. Conclusion There is a U-Shaped association of sUA with all-cause mortality in gout patients. Target sUA of less than 6 mg/dl is rational as it corresponds to the interval of lowest mortality. Randomized trials with mortality as an endpoint are warranted to determine target sUA for gout patients. Reference [1]Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017 Jan;76(1):29-42. Acknowledgements: NIL. Disclosure of Interests None Declared.